Ad-hoc | 20 July 2009 14:08
Eckert & Ziegler Strahlen- und Medizintechnik AG / Preliminary Results/Change in Forecast
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 20.07.2009 - According to preliminary evaluations, Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700) made its highest
six-month turnover to date, EUR 52 million, in the first half of the 2009
fiscal year. It also had its best six-month result to date after taxes and
minority interests at approx. EUR 3.9 million (EUR 1.06 per share), almost
twice the result for the corresponding period last year. The Board of
Directors is therefore increasing the FY 2009 forecast of profits after tax
and minority interests from EUR 1.10 per share or EUR 4 million to
approximately EUR 6.6 million or EUR 1.80 per share. Any special effects
arising from partial or total release of provisions in conjunction with the
legal dispute regarding IBt (EUR 7.1 million) have not been considered in
this forecast.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
This good six-month result is due to the solidification of increases in
turnover and earnings in the core business which became visible in the
first quarter. The core business contributed to a result of approximately
EUR 0.40 per share in the second quarter. To this was added a significant
contribution to earnings and liquidity in the Therapy segment from the
Russian business, and this is expected to continue for the next few
quarters. International Brachytherapy S.A. (IBt), an associated company of
Eckert & Ziegler AG, had recently set up a joint venture with a Russian
state fund corporation to manufacture prostate cancer implants in Russia
and has now begun supplying plants and equipment. Developments in the
largest business segment, Nuclear Medicine and Industry, were also
encouraging. The six-month result after tax and minority interests was EUR
3.1 million, approximately 50% more than was earned in the same period last
year (EUR 2.1 million). This means that Eckert & Ziegler Nuclitec GmbH was
integrated into the Group more quickly and more cheaply than planned.
Further improvements are expected in the second half of the year from
gradual optimization taking place in procurement, logistics and sales. The
Radiopharmaceuticals segment continues to make a profit despite high launch
costs for new products. The exact figures for the six-month period will be
made public on August 4, 2009.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de
20.07.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084138
Fax: 49 30 941084112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, ISIN DE0005659700
WKN: 565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------